What is FDA and Cannabis?

The FDA (Food and Drug Administration) maintains a complex regulatory stance toward cannabis, treating different cannabis-derived products under distinct frameworks. The FDA has not approved cannabis as a safe and effective drug for any indication, though it has approved several cannabis-derived medications. The most significant FDA-approved cannabis product is Epidiolex (cannabidiol), approved in 2018 for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The FDA has also approved synthetic cannabis-based drugs including Marinol and Syndros (dronabinol) and Cesamet (nabilone). For hemp-derived CBD products, the FDA distinguishes between those containing less than 0.3% THC (federally legal under the 2018 Farm Bill) and those exceeding this threshold. However, the FDA has not established regulatory pathways for CBD in foods, dietary supplements, or cosmetics, creating regulatory uncertainty. As of 2024, the FDA has issued warning letters to dozens of companies making unsubstantiated health claims about CBD products. The FDA's position on cannabis research remains cautious but evolving. The agency has streamlined some research approval processes while maintaining strict oversight. Clinical trials for cannabis-based medications must follow standard drug development protocols, including Investigational New Drug (IND) applications. Marijuana remains federally illegal, creating jurisdictional tensions between state-legal cannabis markets and federal oversight. The FDA cannot regulate state-legal marijuana dispensaries directly, though it monitors product safety issues and interstate commerce concerns. Current FDA priorities include studying CBD's long-term effects, potential drug interactions, and establishing science-based regulatory frameworks. The agency has requested additional safety data and conducted public hearings to inform potential rulemaking. This regulatory uncertainty impacts cannabis companies' ability to make health claims, conduct interstate commerce, and access traditional banking services, significantly affecting market valuations and investment decisions across the cannabis industry.